Protocol Number: 77-DK-0096

Title:

Studies on Thyroid Nodules and Thyroid Cancer

Number:

77-DK-0096

Summary:

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer.

The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.

Sponsoring Institute:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: Yes

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA:

Adults and children with known or suspected thyroid neoplasm will be considered for participation. Enrollment will be capped accordingly:

1. Patients with thyroid nodules requiring evaluation and possible biopsy (no more than 30 per year);

2. Patients with recent diagnosis of thyroid cancer requiring consultation and counseling about therapeutic options (no more than 10 per year);

3. Patients with established thyroid cancer requiring specialized studies such as (131)I dosimetry (no more than 5 per year);

4. Enrollment of high risk, non-iodine avid, inoperable thyroid cancer only for purposes of screening for eligibility for other specific thyroid cancer protocols.

EXCLUSION CRITERIA:

1. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma;

2. Patients unable or unwilling to give informed consent

Special Instructions:

Only a limited number of patients are being recruited at the present time. Our major research focus is the diagnosis and treatment of clinically aggressive thyroid cancer. Current research aims are focusing on patients requiring dosimetry measurements, patients with iodine non-avid disease, as well as patients with progressive disease despite optimal prior surgical and radioiodine therapies.

If interested, have your health care provider send a written referral letter summarizing your thyroid disorder plus all applicable laboratory, radiology, and nuclear medicine reports. All biopsy or surgery pathology reports AND relevant slides must be included. This information will be reviewed by Principal Investigator to determine whether you are eligible for protocol enrollment.

Keywords:

Thyroid

Nodules

Cancer

Clinically Aggressive

Radioiodine

Dosimetry

High Dose Therapy

FDG-PET Scanning

Fine Needle Aspiration Biopsy

Recruitment Keyword(s):

None

Condition(s):

Neoplasm Metastasis

Thyroid Neoplasm

Thyroid Nodule

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Institute of Diabetes and Digestive and Kidney Diseases

Contact(s):

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citation(s):

A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer

Sequential serum thyroglobulin determination, (131)I scans and (131)I uptakes after triiodothryonine withdrawal in patients with thyroid cancer

Thyroid cancer: a lethal endocrine neoplasm

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 09/17/2008